SUMMARY Two hundred and two patients with rheumatoid arthritis (RA) starting treatment with large doses of azathioprine (median 300 mg/day) between 1964 and 1974 were followed up until March 1984. All but one patient (99-5%) were traced from either hospital or general practice records; and death certificates, where relevant, were obtained. A comparison group of 202 patients with RA not treated with azathioprine was selected from the diagnostic index of another rheumatology unit and followed up in 1985 to assess their status retrospectively at March 1984. Each patient treated with azathioprine was matched for year of birth, year of diagnosis, sex, and serostatus with a control patient from the latter group. Four lymphoproliferative cancers occurred in the azathioprine treated group compared with two in the control group. Further analysis of these findings suggested an increased risk of lymphoma of one case per 1000 patient years of azathioprine treatment. The lymphoma rates were then compared with those expected based on the incidence in the general population. This comparison suggested a fivefold increase in the RA control group and a 10-fold increase in the azathioprine treated group. There was also an excess of patients with non-lymphoproliferative cancers, including one with myeloma in the azathioprine group (29 v 19), the excess being greater in the group with the longest duration of treatment. This significantly increased risk did not, however, persist on matched analysis, was not related to maximum daily dose, and was not site specific. These results from a possibly unique series of patients treated with high dose azathioprine give some reassurance about the magnitude of the previously postulated carcinogenic risk of such treatment in RA.
Immunosuppressive drugs have been used for the last 30 years in the treatment of patients with severe rheumatoid arthritis (RA). There is evidence that they can reduce synovitis, and further, azathioprine has been shown to be as effective as gold when started early in the disease. Long term treatment with such agents is frequently indicated in order to maintain any remission induced, and hence there is a need to study prospectively the incidence of potentially severe adverse side effects. Any increase in such risk had to be considered in the context of a possible increased risk in patients with RA not treated with azathioprine. There are conflicting results on this subject with some studies finding an increased risk4 5 and others no increase in risk. 6 7 This disparity may reflect methodological differences, with the positive reports coming from the more sensitive method of cohort morbidity analysis. 8 In one of the most recent studies an eightfold increase in incidence of reticuloendothelial cancer in patients with RA was observed,5 though, interestingly, none of the patients that developed a lymphoma had been treated with azathioprine.
Thus it was hoped that by comparing the reticuloendothelial cancer risk in the Newmarket patients, given their unique exposure to high dose azathioprine over a long period, with that of a control group of patients with RA not treated with azathioprine, this particular aspect of azathioprine safety could be usefully evaluated.
Patients and methods

PATIENTS
The exposed group consisted of the original 204 patients from Newmarket, of whom records were available for 202 (99%). Each of these patients (57 (28%) male, 145 (72%) female) had RA and had been treated with azathioprine. The mean age at diagnosis was 43-8 years (SD 19), and 183 (91%) had been recorded as seropositive at some stage in their illness. All had started treatment with azathioprine between 1964 and 1975 and had received this treatment for a median of 35 months (range 1-222) with a median daily dose of 300 mg (range 150-400). Full details of the dosage regimen used have been described previously. 3 Selection of the control group was more problematic. This was not a randomised controlled trial and thus there were no natural local controls. It was therefore necessary to search for an alternative control group of patients with RA for whom a similar duration of follow up information was available. The London Hospital has had a diagnostic index since 1970 and includes about 2500 patients with RA who first attended that hospital between 1948 and 1983. The social class and urban/rural differences in the incidence of reticuloendothelial cancers are insufficiently large9 to bias a comparison of reticuloendothelial cancer incidence between London and Newmarket in either direction. Each azathioprine treated patient was therefore matched to a non-treated patient with RA With these approaches only one patient from the azathioprine group lacked complete follow up data. The follow up of the non-exposed group was initially less satisfactory, with only 70% of these patients having complete follow up data. This is perhaps not surprising given the higher population mobility in the London area. The cancer status for the missing 30% of the non-exposed group was subsequently obtained from the National Health Service central register, and only eight (4%) remained untraced. Death certificates were obtained for all patients known to have died from the Office of Population, Censuses, and Surveys.
Follow up was continued to death, diagnosis of cancer, and for the remainder until 31 March 1984.
ANALYSIS
The analytical methods used allowed for the differences in follow up between the two groups. Each control was given a dummy date for the start of azathioprine treatment. This date was calculated as the time interval after their diagnosis corresponding to the interval between diagnosis and treatment in their matched case. The total number of person years at risk was calculated for each group based from the start (true or dummy) of azathioprine treatment to the end of follow up. The incidence of lymphoproliferative malignancy (ICD codes [200] [201] [202] , and of all cancers, per 1000 person years at risk was then calculated for both groups. The total person years at risk were then subdivided into sex and 10 year age groups to allow the expected lymphoproliferative and all cancer incidence to be calculated based on the appropriate published national rates for the median calendar year of follow up.9 Calculation of the expected incidence in both groups permitted a check on the closeness of matching. Thus the better the matching, the more similar the distribution of the age specific years at risk and hence the closer should be the expected number of cases in both groups.
The analysis was also carried out with the matching retained. If either the case or control in a given pair had developed a cancer before this treatment start day the pair were excluded from the analysis. This applied to 15 pairs: 12 in whom the control had developed cancer before the matched case had started azathioprine and three cases with a cancer history antedating the start of azathioprine. A matched pair analysis was undertaken to obtain the estimate for relative risk based on the number of pairs discordant for cancer-that is, by testing the null hypothesis that there are equal numbers of such pairs with either the azathioprine case or matched control with a cancer. In the azathioprine group the incidence of cancer was further examined in relation to dose in three ways: (a) by total duration of treatment, dividing the group into thirds; (b) by maximum daily dose; (c) by an estimate of total dose obtained by adding together the products of duration and daily dose for each patient. Four total dose ranges were chosen <10 g, 10-50 g, 50-200 g, and >200 g. The trends obtained were examined for group.bmj.com on January 12, 2018 -Published by http://ard.bmj.com/ Downloaded from azathioprine group (29 v 19, 13*4 v 8-3/1000 patient years). The difference in cancer incidence was significant when analysed (ignoring pairing) by the log rank method (X2 ldf 4-7, p=0-031).
Of the 187 remaining pairs, cancer developed in both members of four pairs, in the azathioprine treated patient only in 25 pairs, and in the control only in 15 pairs. This yielded a non-significantly increased relative risk of 1-67 (25/15) with 95% confidence interval 086-3*20. Further, the increased risk overall may be clinically acceptable as it was equivalent to an attributable risk in the azathioprine group of one extra cancer per 217 years of patient observation. Table 3 shows the primary sites of the non-lymphoproliferative cancers in both groups. One other reticuloendothelial tumour, a myeloma, in the azathioprine group developed in a man aged 72; 14 years after finishing a four month course of azathioprine. The distribution by site of non-lymphoproliferative cancers was similar in the two groups. The number of expected non-lymphoproliferative cancers, based on population data, is 15.7 and 17*3 for the azathioprine and control groups, and thus the excess risk of these cancers for both groups was 1 8 and 1-1, interestingly showing no increase in the untreated RA group. Finally, the risk of cancer in the azathioprine group was analysed in relation to different parameters of dose received. Firstly, the group was divided into thirds based on duration of treatment (Table 4 ). There was no trend of increasing length of follow up for those with the longest duration of treatment. In addition, there was no significant trend towards an increased cancer risk with increasing duration. Similarly, there was no trend towards increased risk by maximum daily dose (Table 5 ).
Conversely, there was a statistically significant trend towards cancer with increased estimated total dose, using the categories mentioned earlier (Table 6 ). This apparent inconsistency may be explained by the fact that the group with the longest duration of treatment (Table 4 ) covered the broad range 49-222 months, and hence an effect within this band cannot be ruled out.
Discussion
The main conclusion is that any relative increase in lymphoma risk from azathioprine treatment is likely to be small in relation to the relative increase in 'background' risk in RA generally and is perhaps clinically acceptable. The doses of azathioprine used were twice the currently advised maximum of 2 5 mg/kg daily, and perhaps fears concerning the lymphoma risk from using this agent for treatment of RA are excessive. There is no reason to believe that Newmarket residents were at a lower baseline risk which might have explained the disparity between these results and those of others. 1 The total excess ratio of six lymphoproliferative cancers observed (0-82 expected) in the total study population is similar to the nine observed (1.13 expected) for all reticuloendothelial cancers reported by Prior et al in a similar sized cohort of rheumatoid patients followed up for a similar period. 5 The other conclusion from this study is that a higher overall cancer risk with azathioprine treatment cannot be excluded, especially given the apparent effect of duration of therapy. This possible increase in risk has, however, also to be considered against the following: firstly, the dose/response effect was not consistent, maximum daily dose having no apparent effect, and secondly, there was no site specificity, the primary site for the excess cancers being lung, breast, or skin. There were 12 more deaths from all causes recorded in the treated group, but the overall distribution of deaths by major cause was similar in both groups. In conclusion, the increased lymphoproliferative risk from using high doses of azathioprine in patients with RA is about twice that due to RA alone.
